Pharmaceuticals company Aarti Pharmalabs announced Q1FY27 results Consolidated Financial Highlights: Revenue from Operations: The company reported a net revenue of Rs 53,579.69 lakh in Q1FY27, representing a YoY growth of 38.74% from Rs 38,619.09 lakh in Q1FY26. However, on a QoQ basis, revenue saw a decline of 8.04% from Rs 58,264.40 lakh in Q4FY26. Total Income: Total income for the quarter stood at Rs 53,624.96 lakh, up 38.58% YoY compared to Rs 38,696.22 lakh in Q1FY26. It decreased by 9.22% QoQ from Rs 59,069.56 lakh in Q4FY26. Profit Before Tax (PBT): Consolidated PBT grew to Rs 10,106.02 lakh in Q1FY27, marking a YoY increase of 66.17% from Rs 6,081.73 lakh in Q1FY26 and a QoQ growth of 23.73% from Rs 8,167.86 lakh in Q4FY26. Net Profit: The company posted a net profit of Rs 7,614.27 lakh in Q1FY27, reflecting a significant growth of 65.42% YoY from Rs 4,603.09 lakh in Q1FY26 and a 24.57% increase QoQ from Rs 6,112.41 lakh in Q4FY26. Earnings Per Share (EPS): Basic EPS improved to Rs 8.40 in Q1FY27, compared to Rs 5.08 in Q1FY26 and Rs 6.74 in Q4FY26. Full Year FY26 Performance: For the full year ended March 31, 2026, the company recorded total income of Rs 1,82,918.89 lakh and a net profit of Rs 17,470.73 lakh. Standalone Financial Highlights: Revenue from Operations: Standalone net revenue was Rs 53,458.78 lakh in Q1FY27, reflecting a YoY growth of 42.44% from Rs 37,531.06 lakh in Q1FY26 and a QoQ decrease of 7.78% from Rs 57,970.05 lakh in Q4FY26. Total Income: Total standalone income stood at Rs 53,751.91 lakh, an increase of 42.93% YoY and a decrease of 8.93% QoQ compared to Rs 37,608.19 lakh in Q1FY26 and Rs 59,023.06 lakh in Q4FY26, respectively. Net Profit: Standalone net profit for Q1FY27 reached Rs 7,130.66 lakh, up 49.33% YoY from Rs 4,775.05 lakh in Q1FY26 and up 14.95% QoQ from Rs 6,203.07 lakh in Q4FY26. Business Highlights: Segment Performance: The company operates exclusively within a single reportable segment, "Pharmaceuticals". Capacity Expansion: The Board of Directors approved a capacity addition for the "Development of Intermediate Block" with an estimated capital expenditure (capex) of Rs 149 crore. This project involves a proposed capacity addition of 405 Kl and is expected to be completed within one year. Strategic Rationale: The expansion is intended to serve the company's intermediate and CDMO (Contract Development and Manufacturing Organization) customers. Management Restructuring: The Board approved change in roles for senior management, effective from October 1, 2026. Shri. Rashesh C. Gogri will transition from Non-Executive Director to Managing Director, and Smt. Hetal Gogri Gala will transition from Managing Director to Executive Director, subject to shareholder approval. Equity Allotment: The company allotted 1,35,480 equity shares of Re 1/- each following the exercise of options under its 2023 ESOP plan at an exercise price of Rs 14.10 per share. Result PDF
Pharmaceuticals company Aarti Pharmalabs announced Q4FY26 & FY26 results Standalone Financial Highlights: Total Income: For Q4FY26, standalone total income was Rs 59,023.06 lakh, marking an increase of 38.65% QoQ from Rs 42,569.39 lakh in Q3FY26 and an increase of 11.45% YoY from Rs 52,958.57 lakh in Q4FY25. For FY26, total income stood at Rs 1,81,287.50 lakh, showing a growth of 1.61% YoY over Rs 1,78,414.86 lakh in FY25. Revenue from Operations (Net): Standalone revenue for Q4FY26 reached Rs 57,970.05 lakh, representing a growth of 36.32% QoQ from Rs 42,525.28 lakh and a growth of 9.46% YoY from Rs 52,962.37 lakh. Annual revenue for FY26 was Rs 1,79,755.17 lakh, a growth of 1.48% YoY from Rs 1,77,135.18 lakh. Profit Before Tax (PBT): For Q4FY26, standalone PBT was Rs 8,258.54 lakh, witnessing a growth of 44.01% QoQ compared to Rs 5,734.78 lakh in Q3FY26 and a decline of 27.24% YoY from Rs 11,350.20 lakh in Q4FY25. Annual standalone PBT for FY26 stood at Rs 23,423.90 lakh, down 30.36% YoY from Rs 33,634.11 lakh. Net Profit: Standalone net profit for Q4FY26 was Rs 6,203.07 lakh, up 44.52% QoQ from Rs 4,292.18 lakh and down 30.18% YoY from Rs 8,884.52 lakh. For FY26, net profit reached Rs 17,620.20 lakh, representing a decrease of 31.53% YoY compared to Rs 25,734.88 lakh in FY25. Earnings per Share (EPS): Basic EPS for FY26 was Rs 19.44, compared to Rs 28.39 in the previous year. Consolidated Financial Highlights: Total Income: Consolidated total income for Q4FY26 was Rs 59,069.56 lakh, representing an increase of 36.51% QoQ vs Rs 43,271.38 lakh and a 4.62% increase YoY vs Rs 56,463.66 lakh. For FY26, total income was Rs 1,82,918.89 lakh, a decrease of 13.86% YoY compared to Rs 2,12,350.04 lakh in FY25. Revenue from Operations (Net): Consolidated revenue for Q4FY26 was Rs 58,264.40 lakh, reflecting a 34.79% QoQ growth from Rs 43,227.27 lakh and a 3.35% increase YoY from Rs 56,377.70 lakh. Annual consolidated revenue for FY26 reached Rs 1,81,944.25 lakh, down 13.98% YoY from Rs 2,11,507.45 lakh. Profit Before Tax (PBT): For the quarter Q4FY26, consolidated PBT stood at Rs 8,167.86 lakh, showing an increase of 32.52% QoQ from Rs 6,163.57 lakh and a decline of 28.74% YoY from Rs 11,461.97 lakh. Annual consolidated PBT for FY26 was Rs 23,292.12 lakh, a decrease of 35.42% YoY vs Rs 36,068.95 lakh in FY25. Net Profit: Consolidated net profit for Q4FY26 reached Rs 6,112.41 lakh, marking a 29.96% QoQ increase from Rs 4,703.29 lakh and a 30.81% YoY decline from Rs 8,834.08 lakh. For FY26, annual net profit stood at Rs 17,470.73 lakh, down 35.87% YoY from Rs 27,240.48 lakh. Earnings per Share (EPS): Consolidated basic EPS for FY26 was Rs 19.27, compared to Rs 30.06 in FY25. Business Highlights: Segment Performance: The company operates primarily in a single business segment, which is "Pharmaceuticals". Dividend: The Board of Directors has recommended a final dividend of Rs 2 per equity share (40%) of face value Rs 5 each for the financial year 2025-26. Exceptional Items: The company recorded an incremental provision of Rs 279.49 lakh during the year ended March 31, 2026, on account of the impact of new labour codes. Foreign Exchange Impact: The company recognized a net mark-to-market (MTM) fair value loss of Rs 2,972.94 lakh for FY26 on target redemption forward contracts used for hedging export inflows. Corporate Designation: The Board designated Mr. Sachin Patil as Head - Exports and Mr. Rajendra Pagare as Head - Operations & Compliance as Senior Management Personnel effective May 25, 2026. Auditor Re-appointments: The company re-appointed Smt. Ketki D. Visariya as Cost Auditor and Manish Modi & Associates as Internal Auditor for FY27. Joint Venture: Ganesh Polychem Limited became a joint venture of the company effective April 1, 2025, following an addendum to the Shareholders' Agreement (SHA). Result PDF
Pharmaceuticals company Aarti Pharmalabs announced Q3FY26 results Revenue: Rs 43,227.27 lakh against Rs 53,777.82 lakh during Q3FY25, change -20%. PBT: Rs 6,286.88 lakh against Rs 10,062.56 lakh during Q3FY25, change -38%. PAT: Rs 4,795.56 lakh against Rs 7,398.79 lakh during Q3FY25, change -35%. EPS: Rs 5.29 for Q3FY26. Result PDF
Pharmaceuticals company Aarti Pharmalabs announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Operational Revenue: Rs 5,638 million compared to Rs 5,058 million during Q4FY24, change 11.5%. EBITDA: Rs 1,456 million compared to Rs 1,175 million during Q4FY24, change 23.9%. EBITDA margin: 25.82% for Q4FY25. PBT: Rs 1,146 million compared to Rs 957 million during Q4FY24, change 19.7%. PAT: Rs 883 million compared to Rs 653 million during Q4FY24, change 35.2%. PAT margin: 15.66% for Q4FY25. FY25 Financial Highlights: Operational Revenue: Rs 21,151 million compared to Rs 18,526 million during FY24, change 14.2%. EBITDA: Rs 4,644 million compared to Rs 3,860 million during FY24, change 20.3%. EBITDA margin: 21.96% for FY25. PBT: Rs 3,607 million compared to Rs 3,005 million during FY24, change 20.0%. PAT: Rs 2,724 million compared to Rs 2,169 million during FY24, change 25.6%. PAT margin: 12.88% for FY25. Result PDF